Trial Profile
An Open-Label Clinical Study Evaluating the Long-Term Safety of ALTU-135 for the Treatment of Patients with Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Liprotamase (Primary)
- Indications Cystic fibrosis; Exocrine pancreatic insufficiency
- Focus Adverse reactions
- Acronyms DIGEST S
- Sponsors Anthera Pharmaceuticals; Eli Lilly and Company
- 21 Jul 2014 New trial record